Table.
All data are listed as n (%), unless otherwise indicated.
| All | Tigecycline | No Tigecycline | p | |
|---|---|---|---|---|
| n | 260 | 80 | 180 | |
| BASELINE CHARACTERISTICS | ||||
| Age, median (IQR) | 71 (61–81) | 72 (62–79) | 71 (60–83) | 0.80^^ |
| Gender, female | 162 (62) | 47 (58) | 115 (64) | 0.49 |
| Race | 0.54 | |||
| White, non Hispanic | 141 (54) | 42 (53) | 99 (55) | |
| Black, non Hispanic | 106 (41) | 34 (43) | 72 (40) | |
| Hispanic | 6 (2) | 3 (2) | 3 (2) | |
| Other | 7 (3) | 1 (1) | 6 (3) | |
| Diabetes mellitus | 141 (54) | 43 (54) | 98 (54) | 1.00 |
| Heart disease# | 139 (53) | 40 (50) | 99 (55) | 0.50 |
| Renal failure | 67 (26) | 16 (20) | 51 (28) | 0.17 |
| COPD | 72 (28) | 20 (25) | 52 (29) | 0.55 |
| Malignancy | 38 (15) | 11 (14) | 27 (15) | 0.85 |
| Dementia | 56 (22) | 17 (21) | 39 (22) | 1.00 |
| Immunocompromise† | 19 (7) | 5 (6) | 14 (8) | 0.80 |
| Charlson, median (IQR) | 3 (2–5) | 3 (2–6) | 3 (2–5) | 0.82 |
| Origin | 0.50^ | |||
| skilled nursing facility | 132 (51) | 46 (58) | 86 (48) | |
| home | 80 (31) | 20 (25) | 60 (33) | |
| hospital transfer | 32 (12) | 9 (11) | 23 (12) | |
| long term acute care | 16 (6) | 5 (6) | 11 (6) | |
| Infection | 73 (28) | 27 (34) | 46 (26) | 0.18 |
| Location at time of culture | 0.27 | |||
| emergency department | 90 (35) | 27 (34) | 63 (35) | |
| ward | 117 (45) | 32 (40) | 85 (47) | |
| intensive care unit | 53 (20) | 21 (26) | 32 (18) | |
| Pitt bacteremia score≥4 | 60 (23) | 26 (33) | 34 (19) | 0.025 |
| Days to first positive culture, median (IQR) | 0 (0–3) | 0 (0–2) | 0 (0–3) | 0.93 |
| Urinary drainage | 0.04^ | |||
| physiologic | 92 (35) | 19 (24) | 73 (41) | |
| Foley catheter | 129 (50) | 50 (63) | 79 (44) | |
| intermittent catheterization | 18 (7) | 5 (6) | 13 (7) | |
| permanent urinary diversion* | 21 (8) | 6 (8) | 15 (8) | |
| Urine wbc | 0.12^^^ | |||
| not performed | 71 (27) | 22 (28) | 49 (27) | |
| 0–5 cells/hpf | 13 (5) | 4 (5) | 9 (5) | |
| 5–10 cells/hpf | 13 (5) | 3 (4) | 10 (6) | |
| 10–25 cells/hpf | 33 (13) | 6 (8) | 27 (15) | |
| >25 cells/hpf | 130 (50) | 45 (56) | 85 (47) | |
| OUTCOMES | ||||
| CRKP in other sites*** | ||||
| none | 224 (86) | 60 (75) | 164 (91) | 0.0009 |
| blood | 14 (5) | 7 (9) | 7 (4) | 0.14 |
| respiratory | 9 (3) | 4 (5) | 5 (3) | 0.46 |
| wound | 12 (5) | 9 (11) | 3 (2) | 0.002 |
| other | 2 (1) | 0 (0) | 2 (1) | 1.00 |
| Length of stay, days, median (IQR) | 9 (5–15) | 12 (7–18) | 8 (5–14) | 0.001^^ |
| ICU admission | 119 (46) | 46 (57) | 73 (41) | 0.015 |
| days in ICU, median (IQR)** | 6 (3–13) | 10 (5–16) | 3 (4–9) | |
| Disposition | 0.23^^^^ | |||
| death/hospice | 29 (11) | 13 (16) | 16 (9) | |
| home | 59 (23) | 11 (14) | 48 (27) | |
| skilled nursing facility | 127 (49) | 34 (43) | 93 (52) | |
| long term acute care | 41 (16) | 21 (26) | 20 (11) | |
| transfer other hospital | 4 (2) | 1 (1) | 3 (2) | |
#
coronary artery disease and/or heart failure,
†
10mg/day prednisone or equivalent corticosteroid dosing, solid organ or stem cell transplant recipient,
*
includes suprapubic catheter and ileal conduit.
**
in those patients with an ICU admission.
***
during index admission (totals do not add to 100%, as some patients had CRKP isolated from more than one additional anatomical site). CRKP: carbapenem-resistant K. pneumoniae.
^
pearson.
^^
median test,
^^^
ordinal logistic for those with urinalysis performed,
^^^^
multivariate nominal logistic model adjusted for infection, Pitt score, drainage, and additional CRKP source.